ReviewDrug delivery and translational research2026
Advances in carrier-free nanodrug delivery systems.
Review in Drug delivery and translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Nanotechnology has propelled the development of nanodrug delivery systems (NDDS) with remarkable potential in disease diagnosis and therapy. Nevertheless, conventional NDDS relying on exogenous nano-carriers suffer from intrinsic limitations, including suboptimal drug-loading capacity and biocompatibility issues. In this context, carrier-free nanodrug delivery systems (CFNDDS), constructed through the intrinsic self-assembly of therapeutic molecules, have emerged as a paradigm-shifting alternative. CFNDDS enables drug loading efficiency close to the theoretical maximum, while effectively avoiding carrier-associated toxicity, thereby maximizing drug efficacy. This review meticulously elucidates the fundamental driving forces that regulate CFNDDS self-assembly and summarizes innovative delivery strategies based on single-drug, dual-drug, multi-drug, and prodrug modalities. Furthermore, we provide a comprehensive survey of recent advancements in CFNDDS applications for treating various diseases, including cancer, fatty liver disease, osteoarthritis, atherosclerosis, fibrosis, and antibacterial infections. Analyzing the mechanism of action and application value of CFNDDS from multiple dimensions, perspectives, and levels provides a crucial theoretical basis for developing and researching the clinical use of drugs.
Indexed as
Identifiers
41952012What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.